Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

Calibr's novel 'switchable' CAR-T cell therapy granted FDA's Fast Track designation

Researchers identify a potential target for small cell lung cancer

Researchers identify a potential target for small cell lung cancer

Researchers unravel new mechanism of cell survival in chronic lymphocytic leukemia

Researchers unravel new mechanism of cell survival in chronic lymphocytic leukemia

Blocking nuclear pore complex formation can help selectively kill cancer cells

Blocking nuclear pore complex formation can help selectively kill cancer cells

NCCN publishes new clinical practice guidelines for pediatric Hodgkin lymphoma

NCCN publishes new clinical practice guidelines for pediatric Hodgkin lymphoma

Marrowquant can quantify multiple bone components in histological images

Marrowquant can quantify multiple bone components in histological images

Study identifies hiding place where tumor cells shelter from chemotherapy in childhood leukemia

Study identifies hiding place where tumor cells shelter from chemotherapy in childhood leukemia

Challenges in High Complexity Flow Cytometry

Challenges in High Complexity Flow Cytometry

NCCN's first patient and caregiver resource focused on childhood leukemia

NCCN's first patient and caregiver resource focused on childhood leukemia

Research uncovers potential cause of neurotoxicity due to immunotherapy

Research uncovers potential cause of neurotoxicity due to immunotherapy

Researchers identify new path to defeating chronic myelogenous leukemia

Researchers identify new path to defeating chronic myelogenous leukemia

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

S-pseudotyped VLPs offer promising COVID-19 vaccine platform

SMART researchers discover a new way to manufacture human red blood cells

SMART researchers discover a new way to manufacture human red blood cells

Inherited variation in GATA3 gene is linked to relapse in children with acute lymphoblastic leukemia

Inherited variation in GATA3 gene is linked to relapse in children with acute lymphoblastic leukemia

Study reviews recent insights into the pathogenesis of feline leukemia virus infection

Study reviews recent insights into the pathogenesis of feline leukemia virus infection

Convalescent plasma could be an effective treatment for children with COVID-19

Convalescent plasma could be an effective treatment for children with COVID-19

MD Anderson and Astex Pharmaceuticals partner to accelerate clinical evaluation of leukemia therapies

MD Anderson and Astex Pharmaceuticals partner to accelerate clinical evaluation of leukemia therapies

Acne drug could be a potential treatment for dilated cardiomyopathy

Acne drug could be a potential treatment for dilated cardiomyopathy

Why Black aging matters, too

Why Black aging matters, too

Honeybee venom induces cancer cell death in aggressive breast cancer

Honeybee venom induces cancer cell death in aggressive breast cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.